ARC 1779

04/01/2012 - "Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura."
09/01/2011 - "A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura."
03/01/2011 - "Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura."
05/01/2010 - "The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo."
10/01/2009 - "Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura."

01/01/2022 - "In this study, the inhibitory effects of TAGX-0004 were compared with those of ARC1779 and caplacizumab on in vitro platelet aggregation and thrombus formation. "
07/01/2009 - "Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779."
11/01/2020 - "Novel aptamer to von Willebrand factor A1 domain (TAGX-0004) shows total inhibition of thrombus formation superior to ARC1779 and comparable to caplacizumab."
06/01/2009 - "Archemix Corp's ARC-1779 is an optimized, second-generation, PEGylated aptamer that exerts a novel antithrombotic action through targeting the A1 domain of activated von Willebrand factor (vWF) and inhibiting the binding of platelet receptor glycoprotein Ib, thus reducing platelet adhesion, aggregation and thrombus growth in arterial beds. "

09/01/2010 - "A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease."
08/01/2012 - "The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease."
08/01/2012 - "Blockade of hyperactive von Willebrand factor (VWF) by ARC1779 blunted the platelet drop induced by desmopressin in patients with type 2B von Willebrand disease (VWD). "

09/01/2011 - "ARC1779 was well tolerated without any bleeding at concentrations spanning over three orders of magnitude. "
03/01/2011 - "ARC1779 was generally well tolerated without any signs of bleeding. "
12/04/2007 - "ARC1779 was generally well tolerated, and no bleeding was observed. "
08/01/2011 - "Increased perioperative bleeding and anemia were seen with ARC1779. "

12/04/2007 - "ARC1779 produced dose- and concentration-dependent inhibition of vWF activity and platelet function with duration of effect suitable for the intended clinical use in acute coronary syndromes."
12/04/2007 - "ARC1779 is being developed as a novel antithrombotic agent for use in patients with acute coronary syndromes. "
06/01/2009 - "By inhibiting vWF-dependent arterial thrombogenesis, ARC-1779 has potential therapeutic benefit in acute coronary syndromes and von Willebrand's disease, as well as in vWF-related platelet disorders such as thrombotic thrombocytopenic purpura (TTP) and other thrombotic microangiopathies. "